Drug target identification and validation are critical steps in the drug discovery pipeline. Hence, predicting potential "druggable targets", or targets that can be modulated by some drug, is very relevant to drug discovery. Approaches using structural bioinformatics to predict "druggable domains" have been proposed, but they have only been applied to proteins that have solved structures or that have a reliable model predicted by homology. We show that available protein annotation terms may be used to explore semanticbased measures to provide target similarity searching and develop a tool for potential drug target prediction. We analysed 1,541 human protein drug targets and 29,580 human proteins not validated as drug targets but which share some InterPro annotations with a known drug target. We developed a semantic-based similarity measure by using singular value decomposition over InterPro terms associated with drug targets, performed statistical analyses and built logistic regression models. We present a probabilistic model summarised in a closed mathematical formula that allows human protein drug targets to be predicted with a sensitivity of 89% and a specificity of 67%.
INTRODUCTION
The identification and validation of drug targets are critical steps in the drug discovery pipeline. Thus, it is important to improve the discovery of hidden target similarities or off-target similarities that can help select "druggable targets". Here, we consider "druggable targets" to be those human or pathogen proteins that may be modulated by some orally bioavailable compound. Conversely, "undruggable targets" are those proteins that are considered too difficult to be modulated by some drug. Even "undruggable targets" have been addressed, in particular in oncology studies (Verdine and Walensky, 2007) ; (Schreiber, 2009 ), but it is valuable to distinguish the "more-druggable" and the "less-druggable" targets before incurring substantial expenditure and effort (Cheng et al., 2007) . To identify "druggable" and "undruggable" proteins, some researchers have been developing structurebased approaches to identify "druggable" and "undruggable" binding sites and cavities (Haupt and Schroeder, 2011; Moriaud et al., 2011; Gao et al., 2008) . However, as the majority of drug targets for small molecule therapeutics are formed by proteins with unsolved three-dimensional structures, structure-based design is not possible. Therefore, sequence similarity performs an important role in finding novel "druggable" targets. Indeed, current public resources containing drug target information like the Therapeutic Target Database -TTD (Zhu et al., 2010) and DrugBank (Wishart et al., 2008) provide target similarity searching based only on the BLAST algorithm.
Although high sequence similarity is a good initial guide, it is known that there are also important structural similarities and other correlations even for proteins with low sequence similarity (Vidovic and Schürer, 2009) ; (Krissinel, 2007) ; (Gan et al., 2002) ; (Betts et al., 2001) . Knowledge-based approaches may help develop a classification program. Indeed, in an influential paper, Hopkins and Groom (2002) proposed 130 InterPro entries as sufficient to predict all the druggable human proteins. This proposal, together with studies that evaluate semantic similarity measures based on Gene Ontology annotations (Lord et al., 2003) ; (Chagoyen et al., 2006) , suggest an approach based on investigating semantic similarity measures of protein targets based on their InterPro annotations.
In this paper, we explore semantic similarity across InterPro entries annotated to known drug targets as an alternative to sequence similarity for target similarity prediction. The validated targets were collected from TTD (Zhu et al., 2010) ; DrugBank (Wishart et al., 2008) and KEGG-Drug (Kanehisa et al., 2010) .We represented the targets in a vector space model (VSM) in which targets were recoded as column vectors and the descriptors (rows) were, initially, all the InterPro terms that occur in the target set. The next step was to reduce the dimensionality of the problem. The goal is to select those descriptors that result in the "best" model. The rationale for minimising the number of descriptors in the model is that the resultant model tends to be more efficient when redundant and irrelevant attributes are eliminated (Hosmer and Lemeshow, 2000; Chen et al., 2008) . We applied the cosine similarity measure as described by Chagoyen et al. (2006) to compute the pairwise similarity among the targets represented in a transformed feature space reduced by using Singular Value Decomposition (SVD). We showed that our annotation-based similarity metric is consistent with BLAST and results in better discrimination of the target clusters. Afterwards, we projected other human proteins in the reduced space, calculated the similarity coefficient between each new protein to each validated target and then constructed a control set approximately five times the size of the original validated group. This control set was used in a casecontrol study. It was constructed by selecting a subset of the proteins that resulted in lower maximum similarity coefficients against the drug target set. Then, we applied regression models to minimise the number of the descriptors from the original full data set.
MATERIAL AND METHODS
We constructed a matrix with 1,541 binary vectors that represents known protein drug targets retrieved from public databases (TTD (Zhu et al., 2010) , Drug-Bank (Wishart et al., 2008) and KEGG-Drug (Kanehisa et al., 2010) . Each protein-representing vector is a set of 2,700 binary descriptors, each of them representing an InterPro annotation. Therefore, protein drug targets were recoded as vectors in  m , where m is the number of InterPro descriptors analysed (2,700). In this way, the target database is a sparse matrix M, with dimension m x n, where n is the number of proteins in the data set and each row of the binary vectors indicates the presence or absence of an InterPro annotation:
where x ij is the presence (1) or absence (0) of the InterPro descriptor i on the protein drug target vector j. The matrix M was decomposed by using SVD (Golub and Kahan, 1965) and factorised as M = USV T . The singular values placed in decreasing order along the main diagonal of S are directly related to the independent characteristics within the dataset (Deerwester et al., 1990; Berry et al., 1995; Eldén, 2006) . To transform the matrix M 2700x1541 in an information retrieval system, it was necessary to determine the best low-rank approximation M k in reduced space:
where u e and v e are, respectively, the column vectors of U and the row vectors of V both related to the eth singular value in decreasing order and k is the rank of the matrix M k . We selected k = 320 factors by applying the scree test (Cattell, 1966) to determine the low-rank approximation M k ( Figure  1) . The factorisation provided a reduced dimensionality space in which relationships among the drug targets could be established. The similarity between any pair of drug targets was calculated as the cosine of the angle between the respective target representing vectors on the reduced space. Therefore, the similarity measure of a pair of targets is equivalent to the dot product between the respective rows of the matrix V k S k .
To validate our semantic-based similarity metric, we compared our results with those given by the BLAST algorithm. Figure 2 shows the scatter plot of a distance-like coefficient given by our methodology versus the bit score given by BLAST. To convert the pairwise cosine coefficients into pairwise distance coefficients, we applied the transformation formula proposed by Stuart et al. (Stuart et al., 2002) d ij = -ln((1 + cos ij )/2). The exponential rate of the correlation scatter plot illustrates the known characteristic of SVD as distances become more discriminated -similar entities become more similar and dissimilar entities become more dissimilar in the reduced space vector. The second step was to select the control group, i.e., protein sequences classified as undruggable targets. To do so, we collected from the UniProt (The UniProt Consortium, 2010) 29,580 human proteins that are not validated as drug targets but do share InterPro annotation with any of 1,541 drug targets. Each one of the 29,580 non-target candidate sequences was recoded as a vector in  2700 , where the space dimensionality (2,700) is given by the number of InterPro descriptors considered to generate the query vectors (q). Thus, each query vector was projected into reduced space obtained by SVD; formally, q*=q T U k . Afterwards, we computed the pairwise distance coefficient similarity among the reduced vector queries (q*) and all drug target vectors in the reduced space (M k ), which generated 1,541 pairwise distances for each of the 29,580 nontarget candidate sequences. The maximum pairwise distance of each candidate sequence was selected, and the percentile 75 (p 75 ) of these maximum distances was chosen as the cut-off value to classify a candidate sequence as a non-target protein. All sequences with vector query (q*) with maximum pairwise distance less than 1.2821 (p 75 ) were classified as non-target sequences, becoming the control group, totalling 7,830 proteins. Figure 2 : Correlation scatter plot of the pairwise distance dij between protein vectors (d ij =-ln((1 + cos ij )/2)) and BLAST bit score. The exponential rate may be explained by the known characteristic of SVD as distances becoming more discriminate -similar entities become more similar and dissimilar entities become more dissimilar in the reduced space vector. A negative correlation was expected because the higher the similarity between two proteins, smaller the related distance and the higher the bit score.
The third step of this study was to build a model to predict new human druggable target proteins. This was done by performing a case-control study (Schlesselman, 1982) . Approximately 20% of the 1,541 targets (384 sequences) were extracted randomly for validation, and the remaining 1,157 were used as the case set. For the control group, 7,830 non-target sequences were randomly assigned as either the case set (5,821 sequences) or for model validation (2,009 sequences). Thus, the final sample size was 6978 (5821 + 1157). All InterPro annotations were considered as variable candidates for the model. During the SVD analysis, we used 2,700 InterPro annotations of five types: Family (F), Domain (D), Region (R), Active Site (A) and Binding Site (B). However, to avoid redundancies, we considered only InterPro annotations of F, D or G types during the predictive model construction. Thus, only 2,390 Interpro annotations were considered in the model analysis.
A logistic regression model was developed for the case-control study, allowing feature selection. In addition to feature selection, the logistic model can also be used to predict the probability () that a sequence is a druggable target based on a combination of the k InterPro annotations selected in the model:
(2)
PREDICTING NEW HUMAN DRUG TARGETS BY USING FEATURE SELECTION TECHNIQUES
In Equation (2),  is the probability of a sequence belonging to the drug target group, k is the number of explanatory features (InterPro annotations) significantly selected for the model and  i is the regression coefficient for each InterPro (i = 1, 2, 3 …k). The model-building strategy for the feature selection was an automatic forward stepwise logistic regression performed by SPSS -Statistical Package for the Social Sciences (SPSS Inc., 2008) . Before performing the logistic regression, a univariate analysis was performed using Fisher's exact test on a pre-selected subset of the 2,390 InterPro used in the stepwise logistic regression (Altman, 1991) . Only InterPro annotations with a pvalue less than or equal to 0.05, by Fisher's exact test (univariate analysis), were used in the multivariate analysis. This stringent cut-off was chosen because of the excessive number of candidate features (2,390).
After model building,, definition of the best cutoff for the probabilities calculated by the logistic model in order to classify a new sequence as a potential drug target was made by ROC -'receiver operating characteristic' curve analysis (Altman, 1991) .
RESULTS
The sample size used in the case-control study was composed of 1,157 targets (cases) and 5,821 nontarget sequences (controls), totaling 6,978 proteins. Univariate analysis performed by Fisher's exact test selected 587 InterPro entries from 2,390 annotations initially involved in the study. Some InterPro annotations were selected because their presence increases the chance of a sequence to be a druggable target (as is the case of IPR001828, Table 1 ). Other InterPro annotations were selected because their presence reduced the chance that a sequence would be a druggable target (for example IPR001828, Table  2 ).
From the 587 InterPro entries selected from the univariate analysis that were automatically forwarded to stepwise logistic regression, 66 were identified as independently associated with the drug target status. Table 3 presents the InterPro annotations identified and the  parameters from Equation (2) estimated for the logistic regression model to predict drug target sequences. If the beta value is negative, the presence of the InterPro annotations reduces the chance that a sequence is a druggable target. On the other hand, if the beta value is positive, the presence of the InterPro annotation increases the chance that a sequence is a druggable target. Because the results of logistic model in Equation (2) provide a probability value ranging from 0.0 to 1.0, we need to choose a cut-off value to define if a sequence is in the drug target group. Actually, logistic regression allows us to distinguish those sequences likely or unlikely to be a druggable target, providing a probability value. Usually the cut-off is 0.50, meaning that if the probability that the sequence is in the drug target group is higher than 0.50, then the sequence is classified as a potential druggable target. However, other cut-offs can be used according to the ROC analysis (Figure 3) . The best cut-off in probability is 0.25, which maximises both sensitivity and specificity, being nearest the top left-hand corner of ROC curves.
To validate the model, we reserved 384 known targets and 2,009 control sequences, totalling 2,393 proteins. Classification quality of these sample queries is summarised in Table 4 . The sensitivity of classifying unknown sequences was 89%, and the specificity was 67%. Because we used 0.25 as a cutoff, if the probability model for a query is higher than 0.25, the sequence is classified as a potential druggable target. Figure 3: ROC curve analysis for predicting a druggable target. The best cut-off for maximum sensitivity and specificity is a probability higher than 0.25 (area under the curve = 0.828). 
CONCLUSIONS
We identified 66 features (InterPro entries) that allow retrieval of protein drug targets with a sensitivity of 89% and a specificity of 67%. The model provided a statistical evaluation over the current protein annotation to predict potential drug targets or, at least, potential "druggable targets", meaning proteins that potentially can be modulated by an orally bioavailable drug. The model gives us a closed formula to calculate the probability that a given sequence, described by their biological annotations, is druggable.
Though "druggable targets" are different from "therapeutic drug targets", their prediction is a good contribution to drug development focusing on drug target research.
Our model differs from the approach of Hopkins and Groom (2002) by including not only InterPro annotations that contribute positively to classifying a protein as druggable, but also by including those annotations that contribute negatively. Our model is more restrictive and gives results closer to the proteins that actually are therapeutic drug targets.
